131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma
Recruitment status was Active, not recruiting
RATIONALE: Radioactive drugs, such as 131 I-MIBG, may carry radiation directly to tumor cells and not harm normal cells.
PURPOSE: This phase II trial is studying how well 131 I-MIBG works in treating patients with refractory or relapsed neuroblastoma.
Radiation: iobenguane I 131
|Study Design:||Masking: Open Label
Primary Purpose: Treatment
|Official Title:||I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma, A Phase II Study|
- Ability of iodine I 131 metaiodobenzylguanidine to provide palliative therapy [ Designated as safety issue: No ]
- Acute and late toxicities [ Designated as safety issue: Yes ]
- Disease and symptom responses [ Designated as safety issue: No ]
|Study Start Date:||April 2005|
- Determine if iodine I 131 metaiodobenzylguanidine can provide palliative therapy for patients with refractory or relapsed neuroblastoma.
- Determine the acute and late toxicity of this regimen in these patients.
- Determine disease and symptom responses of patients treated with this regimen.
OUTLINE: This is a compassionate use study.
Patients receive iodine I 131 metaiodobenzylguanidine IV over 2 hours. Beginning 10 days later, patients with low neutrophil counts receive filgrastim (G-CSF) subcutaneously until blood count recovers. Patients with stable or responding disease may receive a second dose of iodine I 131 metaiodobenzylguanidine at least 6 weeks after the first dose.
After completion of study treatment, patients are followed periodically.
PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.
|United States, California|
|UCSF Comprehensive Cancer Center|
|San Francisco, California, United States, 94115|
|United States, Michigan|
|University of Michigan Comprehensive Cancer Center|
|Ann Arbor, Michigan, United States, 48109-0942|
|United States, Pennsylvania|
|Children's Hospital of Philadelphia|
|Philadelphia, Pennsylvania, United States, 19104|
|Study Chair:||Katherine K. Matthay, MD||University of California, San Francisco|
|Investigator:||John M. Maris, MD||Children's Hospital of Philadelphia|
|Investigator:||Robert Goldsby, MD||University of California, San Francisco|